2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-125288
    DS42450411 2247168-13-2 98%
    DS42450411 is an orally active hepcidin production inhibitor with an IC50 of 32 nM. DS42450411 in an acute inflammatory mouse model induced by IL-6, DS42450411 significantly reduces serum hepcidin levels. DS42450411 can be used for studying iron homeostasis.
    DS42450411
  • HY-125316
    AMG-151 1138669-65-4 98%
    AMG-151 (ARRY-403) is a glucokinase agonist with fasting plasma glucose (FPG) lowering activity. AMG-151 showed a significant linear dose-response trend compared with placebo in a randomized, placebo-controlled Phase IIa study. The use of AMG-151 was associated with a higher incidence of hypoglycemia and hypertriglyceridemia. AMG-151 may serve as a potential compound for the inhibition of type 1 diabetes.
    AMG-151
  • HY-125327
    YM-543 1610007-47-0 98%
    YM-543 is a selective SGLT2 inhibitor that effectively reduces hyperglycemia in type 2 diabetic mice through increased urinary glucose excretion. YM-543 demonstrates potent inhibition of both mouse and human SGLT2 activities at nanomolar concentrations. YM-543, when administered orally, significantly improves glucose tolerance in diabetic models and sustains its effects for over 12 hours. YM-543, in combination with other antidiabetic agents like rosiglitazone or metformin, enhances the therapeutic effects on diabetic symptoms. YM-543 does not affect blood glucose levels in normal mice, indicating its specificity for diabetic conditions.
    YM-543
  • HY-125330
    Denagliptin tosylate 811432-66-3 98%
    Denagliptin tosylate is the tosyate salt form of Denagliptin. Denagliptin tosylate is a small molecule dipeptidyl peptidase IV (DPP-4) inhibitor. It can be used in type 2 diabetes research.
    Denagliptin tosylate
  • HY-125404
    DAPK-IN-1 313971-05-0 98%
    DAPK-IN-1 is a DAPK1 and DAPK3 inhibitor. DAPK-IN-1 is applicable to research related to cerebral infarction, myocardial infarction and renal failure.
    DAPK-IN-1
  • HY-125431
    LY 202769 139543-40-1 98%
    LY 202769 (Example 26) is a cholecystokinin (CCK) and gastrin receptor (gastrin receptor) antagonist. LY 202769 is applicable for the research of gastrointestinal diseases and central nervous system diseases.
    LY 202769
  • HY-125432
    Poststatin 135219-43-1 98%
    Poststatin is a pecific prolyl endopeptidase (PEP) inhibitor. Poststatin inhibits bradykinin-degrading enzymes in rat urine.
    Poststatin
  • HY-125507
    F81-1144b 306733-22-2 98%
    F81-1144b is a MMP-1 and MMP-3 inhibitor with IC50 values of 5 nM and 29 nM, respectively. F81-1144b reduces serum and hepatic triacylglycerol levels, decreases the secretion of very-low-density lipoprotein-triacylglycerol, inhibits de novo hepatic fatty acid synthesis, and lowers serum insulin and glucose levels. F81-1144b can be used for the research of hypertriglyceridemia.
    F81-1144b
  • HY-125627
    CP-394531 305822-63-3 98%
    CP-394531 is an efficient and highly selective non-steroidal glucocorticoid receptor (GR) antagonist, with a Ki value of 0.1 nM. CP-394531 has a weak binding to androgen receptor (AR) (Ki = 130 nM), and has almost no effect on progesterone receptor (PR) and estrogen receptors (ERα, ERβ). CP-394531 completely blocks the half-maximal agonistic effect induced by Dexamethasone (HY-14648G), with a Kif of 4.1 nM. CP-394531 can be used to study various diseases such as diabetes, obesity, depression, neurodegenerative diseases, glaucoma and Cushing's disease.
    CP-394531
  • HY-125646
    YH18968 1632498-56-6 98%
    YH18968 is an orally active GPR119 agonist with an EC50 of 2.8 nM for inducing cAMP accumulation. YH18968 activates GPR119, elevates intracellular cyclic adenosine monophosphate levels, stimulates glucagon-like peptide-1 secretion from intestinal L cells, and triggers glucose-dependent insulin secretion from pancreatic β cells. YH18968 improves glucose tolerance in normal mice and diet-induced obese mice. YH18968 can be used for the research of type 2 diabetes.
    YH18968
  • HY-125667
    PA1 1620951-72-5 98%
    PA1 is a photoswitchable epithelial sodium channel (ENaC) blocker. PA1 can switch to cis-PA1 at 400nm and trans-PA1 at 500nm. PA1 inhibits δ/αENaC, αβγENaC, and δβγENaC, with IC50 values of 4.3nM, 90 nM, and 390 nM, respectively.
    PA1
  • HY-125787
    MLS000389544 573965-48-7 98%
    MLS000389544 is a selective and potent methylsulfonylnitrobenzoate thyroid hormone receptor β (TRβ) antagonist that blocks the association of TRβ with steroid receptor coactivator 2 (SRC2).
    MLS000389544
  • HY-125909
    Phenolic acid 29656-58-4 98%
    Phenolic acid is an endogenous metabolite.
    Phenolic acid
  • HY-126110
    (±)11-HDoHE 87018-59-5 98%
    (±)11-HDoHE ((±)11-HDHA) is an ester product.
    (±)11-HDoHE
  • HY-126125
    CHIR-98023 252916-76-0 98%
    CHIR-98023 is a potent, selective and reversible inhibitor of GSK3, with IC50s of 10 nM and 6.7 nM for GSK3α and GSK3β, respectively. CHIR-98023 can improve insulin action and glucose metabolism.
    CHIR-98023
  • HY-126355
    4,7,10,13,16-Docosapentaenoic acid 2313-14-6 98%
    4,7,10,13,16-Docosapentaenoic acid is an endogenous metabolite.
    4,7,10,13,16-Docosapentaenoic acid
  • HY-126416
    Methyl tanshinonate 18887-19-9 98%
    Methyl tanshinonate is a tanshinone, that can be isolated from Salvia miltiorrhiza (S. miltiorrhiza) Bunge (Lamiaceae). Methyl tanshinonate is a potent inhibitor of Mpro enzyme in SARS-CoV (IC50 = 21.1 µM). Methyl tanshinonate can be used for diabetes and SARS-CoV research.
    Methyl tanshinonate
  • HY-126455
    Penicillide 55303-92-9 98%
    Penicillide (Vermixocin A), isolated from Talaromyces derxii cultivated on rice, shows inhibitory activity against acyl-CoA:cholesterol acyltransferase (ACAT).
    Penicillide
  • HY-126487
    H-Arg-Lys-OH 40968-46-5 98%
    H-Arg-Lys-OH is a dipeptide formed from L-arginyl and L-lysine residues.
    H-Arg-Lys-OH
  • HY-126551
    Butenoyl-PAF 474944-25-7 98%
    Butenoyl-PAF is a phospholipid analog of platelet activating factor (PAF-like) that is generated in oxidized low-density lipoprotein (DLDR). Butenoyl-PAF can activate cells that express human PAF receptors, such as neutrophils, monocytes, and platelets, and it stimulates an increase in intracellular calcium ion concentration.
    Butenoyl-PAF
Cat. No. Product Name / Synonyms Application Reactivity